Phase 3Completed
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. (V-Mono)
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 350 enrolled
- Conditions
- Hypercholesterolemia
- Interventions
- Inclisiran; Ezetimibe; Matching Placebo for Inclisiran; Matching Placebo for Ezetimibe
- Ages
- adults, older adults
- Registry
- NCT05763875
Full record on ClinicalTrials.gov
From the registry
CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.
Primary outcomes
- Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
History
Last registry update
Results first posted
Primary completion
Started
Registered